JPMorgan raised the firm’s price target on Medline (MDLN) to $53 from $50 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline price target raised to $60 from $55 at Tigress Financial
- Medline 75M share Secondary priced at $41.00
- Medline announces launch of secondary offering of Class A common stock
- Medline files to sell 75M shares of Class A common stock for holders
- Medline price target raised to $56 from $52 at Truist